<DOC>
	<DOCNO>NCT02028338</DOCNO>
	<brief_summary>To assess safety dapivirine ( 25 mg ) administer via silicone vaginal ring HIV-uninfected adolescent female , insert every 4 week 12 week study product use</brief_summary>
	<brief_title>Phase 2a Study Dapivirine Ring Adolescent Females</brief_title>
	<detailed_description>MTN-023/IPM 030 Phase 2a , two-arm , placebo-controlled , double-blinded , multi-site , randomized trial dapivirine vaginal ring ( VR ) versus placebo VR . The clinical trial design assess safety dapivirine ( 25 mg ) administer via silicone vaginal ring ( primary objective ) evaluate acceptability dapivirine placebo VR sexually experience , HIV-uninfected adolescent female , insert every 4 week 12 week study product use . Approximately 96 participant randomize 3:1 ratio receive either silicone elastomer vaginal ring contain 25 mg dapivirine placebo VR . The ring replace every 4 week 12 week study product use period . Use VR provide sustain delivery microbicides novel investigational method prevention heterosexual transmission HIV woman . This drug delivery method may circumvent potential difficulty relate adherence daily coitally-dependent us microbicide regimen .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Age 15 17 year ( inclusive ) Enrollment , verify per site SOPs 2 . Able willing provide write informed assent/consent able obtain write parental guardian permission ( specify site SOP ) screen enroll MTN023/IPM 030 3 . Able willing provide adequate locator information , define site SOPs 4 . Able communicate speak write English 5 . Able willing comply study procedural requirement 6 . Per participant report Screening Enrollment , willing abstain insert anything vagina 72 hour prior followup visit , include abstain penilevaginal intercourse . Note : In event vaginal ring expel require reinsertion , reposition vaginal ring permit 7 . In general good health determine Investigator Record ( IoR ) /designee Screening Enrollment 8 . Assessment onset progression puberty , measure Tanner stage 4 5 Screening , per participant report and/or clinician assessment 9 . HIVuninfected base test perform Screening Enrollment ( per protocol algorithm Appendix II ) 10 . Per participant report Screening , history sexual intercourse ( least one episode participant 's lifetime ) 11 . Per participant report Screening Enrollment , agree use condom sexual intercourse 12 . Negative pregnancy test Screening Enrollment 13 . Per participant report , use effective method contraception least 30 day ( inclusive ) prior Enrollment , intend continue use effective method duration study participation ; effective method include : hormonal method ( except contraceptive ring ) intrauterine device ( IUD ) sterilization ( participant , define site SOPs ) 14 . At Screening Enrollment , participant state willingness refrain insert follow vaginal product and/or object vagina ; spermicide , diaphragm , contraceptive vaginal ring , menstrual cup , cervical cap ( vaginal barrier method ) , douche , lubricant , 5 day prior Enrollment throughout duration study participation . Note : Neither use tampon sex toy , participant engagement coitus restrict . 15 . At Screening Enrollment , agree participate research study involve drug , medical device , vaginal product , vaccine duration study participation , unless approve PSRT 1 . Per participant report Screening , intend follow study participation period : 1. become pregnant 2. relocate away study site 3. travel away study site 4 consecutive week 2 . Diagnosed urinary tract infection ( UTI ) and/or reproductive tract infection ( RTI ) Screening and/or Enrollment . Note : Otherwise eligible participant diagnose UTI Screening offer treatment may enrol complete treatment symptom resolve . If treatment complete symptom resolve within 56 day obtain informed consent Screening , participant may enrol . 3 . Diagnosed pelvic inflammatory disease and/or sexually transmit infection ( STI ) require treatment per current Centers Disease Control Prevention ( CDC ) guideline within 60 day Enrollment ( inclusive ) 4 . At Enrollment , clinically apparent Grade 2 high pelvic exam finding ( observe study staff ) ** Note : Cervical bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment IoR/designee consider expect nonmenstrual bleeding exclusionary . Note : Otherwise eligible participant exclusionary pelvic exam finding may enrolled/randomized finding improve nonexclusionary severity grade resolve . If improvement nonexclusionary grade resolution document within 56 day provide informed consent screening , participant may enrol . 5 . Participant report and/or clinical evidence follow : 1 . Known adverse reaction study product ( ever ) 2 . Known HIVinfected partner 3 . Nontherapeutic injection drug use 12 month prior Screening 4 . The use HIV Postexposure prophylaxis ( PEP ) and/or Preexposure prophylaxis ( PrEP ) within 6 month prior Enrollment 5 . Currently breastfeed 6 . Last pregnancy outcome within 90 day less Screening 7 . Participation research study involve drug , medical device , vaginal product , vaccine , within 60 day Screening 8 . Participant report 3 penilevaginal sexual partner month prior Screening 9 . At Enrollment , determine IoR/designee , significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease 6 . Has follow Grade 1 higher* laboratory abnormality Screening Visit : 1 . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) 2 . Creatinine 3 . Hemoglobin 4 . Platelet count Note : Otherwise eligible participant exclusionary test may retested screen process . Please see MTN023/IPM 030 SSP additional detail . 7 . Has condition , opinion IoR/designee , would preclude informed assent/consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective Division AIDS Table Grading Severity Adult Pediatric Adverse Events Version 1.0 , December , 2004 ( Clarification date August 2009 ) **Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 )</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>